Ma Tiantian, Yang Zhikai, Li Shaomei, Pei Huaying, Zhao Jinghong, Li Yi, Xiong Zibo, Liao Yumei, Zhao Zhanzheng, Xiao Jing, Li Ying, Lin Qiongzhen, Zheng Zhaoxia, Duan Liping, Fu Gang, Guo Shanshan, Hu Wenbo, Li Yulin, Sun Fuyun, Zhao Nan, Wang Qin, Ji Tianrong, Zhang Beiru, Yu Rui, Hao Li, Liu Guiling, Zuo Li, Zhao Huiping, Wang Caili, Deng Lirong, Chen Hongyu, Li Li, Shen Yulan, Zhang Yong, Wang Lihua, Yan Yan, Ma Zhigang, Li Yingping, Zhang Xianchao, Wang Xuejian, Liu Yirong, Gao Xinying, Xu Zhonggao, Zhang Li, Du Shutong, Zhao Cui, Chen Xiaoli, Li Hongyi, Yue Yingli, Chen Shanshan, Ma Yingchun, Wei Yuanyuan, Zhou Jingwei, Lv Jie, Zheng Yingdong, Zhu Sainan, Zhao Minghui, Dong Jie
Renal Division, Department of Medicine, 26447Peking University First Hospital, Beijing, China.
Institute of Nephrology, 26447Peking University, Beijing, China.
Perit Dial Int. 2022 Jan;42(1):75-82. doi: 10.1177/0896860820962901. Epub 2020 Nov 28.
The primary objective of the Peritoneal Dialysis Telemedicineassisted Platform Cohort (PDTAP) Study is to explore potential predictors and their effects on patient survival, technique survival, and the occurrence of infectious and noninfectious complications.
The PDTAP study is a national-level cohort study in China. A newly developed PD telemedicine application provided a unique and convenient way to collect multicenter, structured data across units.
The PDTAP study was underway in 27 hospitals from 14 provinces located at 7 geographical regions (northwest, northeast, north, central, southwest, southeast, and south) in China.
Our study aims to enroll at least 7000 adult patients with end-stage renal disease receiving PD.
Approval has been obtained through the ethics committees of all hospitals. All participants signed the informed consent form after the center had received ethics board approval in accordance with the Declaration of Helsinki.
Patient survival, technique survival, hospitalization, and the occurrence of infectious and noninfectious complications.
The PDTAP study aims to explore potential predictors and their effects on patient survival, technique survival, and infectious and noninfectious complications using a newly developed PD telemedicine system to collect multicenter, structured data in real-world practice. Substantial and transformable findings in relation to PD practices were expected. This study also developed a national-level infrastructure for further collaboration and ancillary investigation.
腹膜透析远程医疗辅助平台队列(PDTAP)研究的主要目的是探索潜在预测因素及其对患者生存率、技术生存率以及感染性和非感染性并发症发生情况的影响。
PDTAP研究是一项中国国家级队列研究。新开发的腹膜透析远程医疗应用程序提供了一种独特且便捷的方式来收集跨单位的多中心结构化数据。
PDTAP研究在中国7个地理区域(西北、东北、华北、华中、西南、东南和华南)14个省份的27家医院开展。
我们的研究旨在招募至少7000名接受腹膜透析的终末期肾病成年患者。
已获得所有医院伦理委员会的批准。所有参与者在中心按照《赫尔辛基宣言》获得伦理委员会批准后签署了知情同意书。
患者生存率、技术生存率、住院情况以及感染性和非感染性并发症的发生情况。
PDTAP研究旨在利用新开发的腹膜透析远程医疗系统在实际临床中收集多中心结构化数据,探索潜在预测因素及其对患者生存率、技术生存率以及感染性和非感染性并发症的影响。预计会得出与腹膜透析实践相关的重要且可转化的研究结果。本研究还建立了一个国家级基础设施,以促进进一步的合作和辅助研究。